Tumor-targeting salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy

Cell Cycle

Volumn 13, Issue 24, 2014, Pages 3958-3963

  Yano, Shuya ^a,b,c   Zhang, Yong ^a   Zhao, Ming ^a   Hiroshima, Yukihiko ^a,b   Miwa, Shinji ^a,b   Uehara, Fuminari ^a,b   Kishimoto, Hiroyuki ^c   Tazawa, Hiroshi ^d   Bouvet, Michael ^b   Fujiwara, Toshiyoshi ^c   Hoffman, Robert ^a,b  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cell cycle; Chemotherapy; Decoy; FUCCI; GFP; Imaging; RFP; S. typhimurium A1 R; Tumor targeting bacteria

Indexed keywords

CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CHEMOSENSITIZATION; CONTROLLED STUDY; FLUORESCENCE IMAGING; FLUORESCENCE UBIQUITINATION BASED CELL CYCLE INDICATOR IMAGING; IN VIVO STUDY; MONOLAYER CULTURE; MONOTHERAPY; MOUSE; NONHUMAN; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; TIME LAPSE IMAGING; TUMOR VOLUME; ANIMAL; DRUG SCREENING; HUMAN; INTERPHASE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; STOMACH NEOPLASMS; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS); MUS MUSCULUS; SALMONELLA TYPHIMURIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; INTERPHASE; MICE; MICE, NUDE; SALMONELLA TYPHIMURIUM; STOMACH NEOPLASMS; TIME-LAPSE IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920609390     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.964115     Document Type: Article

References (34)

1. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, et al. Visualizing spatiotemporal dynamics of multicellular cell cycle progression. Cell 2008; 132:487-98; PMID:18267078; http://dx.doi. org/10.1016/j.cell.2007.12.033
2. Yano S, Zhang Y, Miwa S, Tome Y, Hiroshima Y, Uehara F, Yamamoto M, Suetsugu A, Kishimoto H, Tazawa H, et al. Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. Cell Cycle 2014; 13:2110-9; PMID:24811200; http:// dx.doi.org/10.4161/cc.29156
3. 1 resulting in chemoresistance demonstrated by real-time FUCCI imaging. Cell Cycle 2014; 13:953-60; PMID:24552821; http://dx.doi.org/ 10.4161/cc.27818
4. 2/M phases. Clin Cancer Res 2013; 19:6495-505; PMID:24081978; http://dx.doi.org/ 10.1158/1078-0432.CCR-13-0742
5. William Coley. Available from: http://en.wikipedia. org/wiki/William-Coley [Last accessed 12 December 2013].
6. Hoffman RM, Zhao M. Methods for the development of tumor-targeting bacteria. Expert Opin Drug Discov 2014; 9:741-50; PMID:24949888; http://dx.doi.org/ 10.1517/17460441.2014.916270
7. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003; 4:548-56; PMID:12965276; http://dx.doi.org/10.1016/ S1470-2045(03)01194-X
8. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57:4537-44; PMID:9377566
9. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20:142-52; PMID:11773163; http://dx.doi.org/ 10.1200/JCO.20.1.142
10. Zhao M, Yang M, Li X-M, Jiang P, Baranov E, Li S, Xu M, Penman S, Hoffman RM. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFPexpressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102:755-60; PMID:15644448; http:// dx.doi.org/10.1073/pnas.0408422102
11. Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 2007; 104:10170-4; PMID:17548809; http://dx.doi.org/10.1073/ pnas.0703867104
12. Zhao M, Yang M, Ma H, Li X, Tan X, Li S, Yang Z, Hoffman RM. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006; 66:7647-52; PMID:16885365; http://dx.doi. org/10.1158/0008-5472.CAN-06-0716
13. Uchugonova A, Zhao M, Zhang Y, Weinigel M, Konig K, Hoffman RM. Cancer-cell killing by engineered Salmonella imaged by multiphoton tomography in live mice. Anticancer Res 2012; 32:4331-8; PMID: 23060555
14. Liu F, Zhang L, Hoffman RM, Zhao M. Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle 2010; 9:4518-24; PMID:21135579; http://dx. doi.org/10.4161/cc.9.22.13744
15. Nagakura C, Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM. Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res 2009; 29:1873-8; PMID:19528442
16. Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, McElroy M, Bouvet M, Hoffman RM. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 2010;164:248-55; PMID:19766244; http://dx.doi.org/10.1016/j.jss.2009. 02.023
17. Matsumoto Y, Miwa S, Zhang Y, Hiroshima Y, Yano S, Uehara F, Yamamoto M, Toneri M, Bouvet M, Matsubara H, et al. Efficacy of tumor-targeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. J Cell Biochem 2014; 115:1996-2003.
18. Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Hoffman RM. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem 2009;106:992-8; PMID:19199339; http://dx.doi.org/ 10.1002/jcb.22078
19. Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Kishimoto H, Bouvet M, Hoffman RM. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle 2009; 8:870-5; PMID:19221501; http://dx.doi.org/10.4161/cc.8.6.7891
20. Kimura H, Zhang L, Zhao M, Hayashi K, Tsuchiya H, Tomita K, Bouvet M, Wessels J, Hoffman RM. Targeted therapy of spinal cord glioma with a geneticallymodified Salmonella typhimurium. Cell Prolif 2010; 43:41-8; PMID:19922490; http://dx.doi.org/10.1111/ j.1365-2184.2009.00652.x
21. Hiroshima Y, Zhao M, Zhang Y, Maawy A, Hassanein MK, Uehara F, Miwa S, Yano S, Momiyama M, Suetsugu A, et al. Comparison of efficacy of Salmonella typhimurium A1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells. Cell Cycle 2013; 12:2774-80; PMID:23966167; http://dx.doi. org/10.4161/cc.25872
22. Hiroshima Y, Zhao M, Maawy A, Zhang Y, Katz MH, Fleming JB, Uehara F, Miwa S, Yano S, Momiyama M, et al. Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patientderived orthotopic xenograft (PDOX). J Cell Biochem 2014; 115:1254-61; PMID:24435915; http://dx.doi. org/10.1002/jcb.24769
23. Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle 2005; 4:269-78; PMID:15655345
24. Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer 2003; 89:1147-51; PMID:14520435; http://dx.doi.org/10.1038/sj.bjc.6601256
25. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today 2003; 8:1104-7; PMID:14678733; http://dx.doi.org/10.1016/S1359-6446(03)02806-X
26. Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle 2008; 7:1307-12; PMID:18487952; http://dx.doi.org/ 10.4161/cc.7.10.6250
27. Blagosklonny MV. Teratogens as anti-cancer drugs. Cell Cycle 2005; 4:1518-21; PMID:16258270; http:// dx.doi.org/10.4161/cc.4.11.2208
28. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrugresistant cells but protects normal cells. Leukemia 2001; 15:936-41; PMID:11417480; http://dx.doi.org/ 10.1038/sj.leu.2402127
29. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia 2006; 20:385-91; PMID:16357832; http://dx.doi.org/10.1038/sj.leu. 2404075
30. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007; 6:1684-90; PMID:18344680; http://dx.doi.org/ 10.4161/cbt.6.11.5167
31. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222-33; PMID:21447859
32. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget 2010; 1:639-50; PMID:21317459
33. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011; 2:1352-67; PMID:22267462
34. Blagosklonny MV. Antagonistic drug combinations that select against drug resistance: from bacteria to cancer. Cancer Biol Ther 2007; 6:1013-4; PMID: 17646740; http://dx.doi.org/10.4161/cbt.6.7.4340